Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: Relation to response and HBV genotype

Antiviral Therapy

Volumn 17, Issue 1, 2012, Pages 9-17

  Sonneveld, Milan J ^a   Rijckborst, Vincent ^a   Cakaloglu, Yilmaz ^b   Simon, Krzysztof ^c   Heathcote, E Jenny ^d   Tabak, Fehmi ^e   Mach, Tomasz ^f   Boucher, Charles A B ^a   Hansen, Bettina E ^a   Zeuzem, Stefan ^g   Janssen, Harry L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ISTANBUL UNIVERSITY   (Turkey)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

^d UNIVERSITY OF TORONTO   (Canada)

^e ISTANBUL UNIVERSITY   (Turkey)

^f JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2B; VIRUS DNA;

ADULT; ARTICLE; BLOOD LEVEL; CHRONIC PATIENT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LONG TERM CARE; LONG TERM FOLLOW UP; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIROTHERAPY;

ADULT; ANTIVIRAL AGENTS; BIOMARKERS, PHARMACOLOGICAL; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84856203453     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1887     Document Type: Article

References (30)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359:1486-1500.
2. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539. (Pubitemid 46374607)
4. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365:123-129. (Pubitemid 40091801)
5. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137:2002-2009.
6. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334:1422-1427. (Pubitemid 26157437)
7. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39:804-810. (Pubitemid 38337661)
8. Wong VW, Wong GL, Yan KK, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51:1945-1953.
9. Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis 2004; 24 Suppl 1:3-10. (Pubitemid 38738352)
10. Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128:1890-1897. (Pubitemid 40824700)
11. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126:1750-1758. (Pubitemid 38736340)
12. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44:675-684. (Pubitemid 44433724)
13. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5:1462-1468. (Pubitemid 350181604)
14. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49:1151-1157.
15. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49:1141-1150.
16. Rijckborst V, Ter Borg MJ, Cakaloglu Y, et al. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2010; 105:1762-1769.
17. Lau G, Marcellin P, Brunetto M, et al. On-treatment monitoring of HBsAg levels to predict response to peginterferon alfa-2 in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2009; 50:S333.
18. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52:1251-1257.
19. Moucari R, Martinot-Peignoux M, Mackiewicz V, et al. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther 2009; 14:1183-1188.
20. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAgpositive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135:459-467.
21. Pas SD, Fries E, De Man RA, Osterhaus AD, Niesters HG. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 2000; 38:2897-2901. (Pubitemid 30640570)
22. Nguyen T, Desmond P, Locarnini S. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int 2009; doi: 10.1007/s12072-009-9149-7
23. Brunetto MR. A new role for an old marker, HBsAg. J Hepatol 2010; 52:475-477.
24. Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52:508-513.
25. Jaroszewicz J, Serrano BC, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52:514-522.
26. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010; 52:1232-1241.
27. Moucari R, Korevaar A, Lada O, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009; 50:1084-1092.
28. Sugiyama M, Tanaka Y, Kato T, et al. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 2006; 44:915-924. (Pubitemid 46489556)
29. Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101:297-303. (Pubitemid 43381671)
30. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52:454-461.